NCT01438073View on ClinicalTrials.gov

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Hypogonadotropic HypogonadismHealthy Postmenopausal WomenAgonadism
Interventions
DRUG

kisspeptin 112-121

24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)

DRUG

GnRH

Single intravenous dose of GnRH (2.5-250 ng/kg)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01438073 - Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling | Biotech Hunter | Biotech Hunter